Evaluation of the tolerability and efficacy of a noncompetitive, reversible inhibitor of the alpha-amylase and alpha-glucosidase enzymes with a specific, standardized polyphenolic composition on the modulation of postprandial glycemic peaks in overweight patients with impaired fasting glucose